Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Katherine LongardnerBrenton A WrightAljoharah AlakkasHyeri YouRonghui XuLin LiuFatta B NahabPublished in: PloS one (2023)
PDP patients receiving pimavanserin had lower mortality than untreated patients. We found no other clear differences in clinical characteristics to explain the mortality risk. Prospective randomized trials are needed to definitively identify the optimal PDP treatment regimen and associated risks.